Aktienanalyse zu Lantheus Holdings Inc (LNTH)LNTHLantheus Holdings Inc

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company, dedicated to helping clinicians find, fight, and follow disease to deliver better patient outcomes. Its product categories include oncology, neurology, cardiology, and strategic partnerships and others. Its products include PYLARIFY, Neuraceq, and DEFINITY. PYLARIFY TruVu is indicated for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated serum prostate-specific antigen (PSA). Neuraceq is an Alzheimer's disease radiodiagnostic. Its commercial products are used by cardiologists, internists, neurologists, nuclear medicine physicians, oncologists, radiologists, sonographers, technologists, and urologists across a range of clinical care settings. Its diagnostic products provide information that enables healthcare professionals (HCPs) to better detect, characterize, or rule out diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Lantheus Holdings Inc is currently priced at $99.70, which is below the analyst price target of $102.50, indicating potential for short-term gains. However, the RSI is at 28.051, suggesting the stock is oversold and may not have immediate upward momentum. The recent acquisition news by Curium for $102.50 per share adds a layer of uncertainty, as the stock is now more influenced by this deal than its fundamentals. Given the downgrade by multiple analysts and the significant hedge fund selling activity (up 2127.26%), it is prudent to hold rather than buy at this moment.

4 analysts cover LNTH: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 82.17.